Marisa Wexler, MS, senior science writer —

Immunovant will use a $200 million strategic investment from Roivant Sciences to advance IMVT-1401, its investigational therapy for myasthenia gravis (MG) and other autoimmune conditions. A pivotal clinical trial testing IMVT-1401 in people with MG is expected to be launched within the next 12 months, according to…

A very rare case of a myasthenia gravis (MG) crisis caused by the Moderna COVID-19 vaccine was described recently by researchers at St. Joseph’s Regional Medical Center in Paterson, New Jersey. “Although numerous studies have observed the relationship between active COVID infections and MG exacerbations, no known studies or…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

Following a review of available clinical data, Immunovant has announced plans to resume clinical testing of the investigational medication IMVT-1401 in myasthenia gravis (MG) and other autoimmune conditions. Following discussions with regulatory agencies, the company is planning to launch a potentially pivotal trial of IMVT-1401 in…

People with myasthenia gravis (MG) who have difficulty swallowing are more likely to have poor clinical outcomes, according to a recent study. Data from the study also indicates that low levels of albumin — a protein found in the blood that helps transporting hormones and other key molecules in…

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Many people with myasthenia gravis (MG) experience unusual fatigue, including those with pure ocular disease or with…

When used over long periods of time, Soliris (eculizumab) does not increase the risk of infections in people with generalized myasthenia gravis (gMG), according to a new analysis of clinical trial data. Findings from this post hoc analysis were presented this week at the 2021 MDA Virtual Clinical…

The U.S. Food and Drug Administration (FDA) is now reviewing an application from Argenx that seeks approval of efgartigimod (ARGX-113) to treat people with generalized myasthenia gravis (gMG). An agency decision is expected on or before Dec. 17. “This is an important milestone for argenx in our…

In a $3.05 billion deal, Horizon Therapeutics will acquire Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune diseases such as myasthenia gravis (MG), the two companies announced. Horizon plans to advance inebilizumab, already approved for treating another rare autoimmune disease, as a therapy for decreasing disease activity…

After unanimous votes by the boards of directors of both companies, AstraZeneca has announced it will acquire Alexion Pharmaceuticals. If the acquisition gets all needed regulatory clearances, as well as approvals by the shareholders of both companies, the deal is expected to be finalized in the third quarter…